logo
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer

MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer

Yahoo11-07-2025
New report adds to growing evidence of iNKT cell therapy's potential in solid tumors
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the publication of another landmark case in Nature's Oncogene describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer, following treatment with agenT-797, MiNK's allogeneic iNKT cell therapy.
Complete remission after failure on platinum-based chemotherapy, autologous stem cell transplant, and multiple ICIs (anti–PD-1, anti–CTLA-4, and anti–TIGIT)
The publication, titled 'Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor,' presents a patient case from MiNK's clinical trial (NCT05108623). The patient had progressed after multiple lines of therapy—including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors (anti–PD-1, anti–CTLA-4, and anti–TIGIT)—and received a single infusion of agenT-797 alongside nivolumab. The patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later. Donor iNKT cells were detectable up to six months post-infusion, and treatment was well-tolerated with no cytokine release syndrome (CRS) or graft-versus-host disease (GVHD).
'This case exemplifies the powerful potential of iNKT cells in treating even the most challenging cancers,' said Dr. Benjamin Garmezy, Assistant Director of Genitourinary Research for Sarah Cannon Research Institute at SCRI Oncology Partners. 'We observed a remarkable response in a patient who had exhausted standard and experimental treatments, offering compelling evidence to further pursue clinical studies of iNKT cell therapies in solid tumors.'
Durable Responses & Immune Activation in Solid Tumors with Allo-iNKT Therapy
These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors. At the 2025 inaugural AACR Immuno-Oncology meeting, MiNK presented data from its Phase 2 trial in 2L gastric cancer, demonstrating immune activation, increased tumor infiltration, and early signals of tumor control in patients previously refractory to checkpoint inhibitors. Notably, extended survival beyond 12 months was observed in several patients—an outcome rarely seen in this setting. These clinical observations were further reinforced in a separate peer-reviewed case report published in Oncogene, which described a patient with metastatic gastric cancer who achieved a 42% tumor reduction and more than nine months of progression-free survival following a single infusion of agenT-797 in combination with nivolumab.
Together, these data highlight the potential of agenT-797 to reshape the tumor microenvironment and deliver durable clinical activity, even in heavily pretreated, immunotherapy-resistant cancers. The ongoing Phase 2 trial in gastric cancer (NCT06251973) is actively enrolling, with additional readouts expected in upcoming months. You can access the full publication here.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company advancing a new class of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK's proprietary platform is designed to restore immune balance and drive cytotoxic responses across cancer, immune-mediated diseases, and pulmonary immune failure. The company's lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical development for graft-versus-host disease (GvHD), solid tumors, and severe pulmonary inflammation. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable highly specific immune targeting across tumor and tissue types. With a scalable manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to delivering accessible, durable, and broadly applicable immune reconstitution therapies. For more information, visit www.minktherapeutics.com or follow us on X @MiNK_iNKT. Information important to investors is routinely posted to our website and social media channels.
About AgenT-797
AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as 'master regulators,' combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors.
Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al., AACR IO 2024; Oncogene, 2024), as well as reduce inflammation in critically ill patients with severe respiratory pathology (Nature Communications, 2024).
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Agenus with no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
CONTACT: Investor Contact 917-362-1370 investor@minktherapeutics.com Media Contact 781-674-4428 communications@minktherapeutics.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Marvell Stock Is Soaring—Here's Why
Marvell Stock Is Soaring—Here's Why

Yahoo

time4 minutes ago

  • Yahoo

Marvell Stock Is Soaring—Here's Why

Shares of Marvell Technology (MRVL) soared on Wednesday after Morgan Stanley raised its price target on the chipmaker's stock, citing the 'exceptional' strength of AI demand. Morgan Stanley analyst Joseph Moore on Wednesday raised his Marvell price target by about 10% to $80 while maintaining an 'equal weight' rating. 'Marvell is firmly in the AI winners camp, and sentiment has swung aggressively negative compared to a few months ago,' Moore wrote. 'We are more excited for their opportunity in optical, which brings higher margin and durability vs. their ASIC opportunity, which has disappointed.' (ASIC refers to application-specific integrated circuit, a class of customizable chip that combines several circuits to perform tasks that would otherwise require multiple interconnected chips.) Marvell shares were up more than 9% in recent trading, making it the best-performing stock in the Nasdaq 100. Despite Wednesday's gain, Marvell shares are down about 23% since the start of the year. Marvell is just one of several semiconductor stocks Moore expects to benefit from strong AI demand over the next year. He also raised his 12-month price targets on Nvidia (NVDA) by 17%, Broadcom (AVGO) by 25%, Astera Labs (ALAB) by 26%, and Advanced Micro Devices (AMD) by more than 50%. All of those stocks were also trading in the green on Wednesday. (Read Investopedia's full coverage of today's trading here.) 'While stock prices have moved higher, our conviction on AI spend durability in 2026 continues to grow,' Moore wrote. Google parent Alphabet (GOOG) last week raised its full-year capital expenditures forecast, citing the need to accelerate data center buildouts to meet seemingly insatiable demand for AI and cloud computing. Investors will get more updates on the strength of AI investment after markets close on Wednesday when tech giants Microsoft (MSFT) and Meta (META) report earnings. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

SolarEdge and Solar Landscape Sign Strategic Agreement for American-Manufactured SolarEdge Technology
SolarEdge and Solar Landscape Sign Strategic Agreement for American-Manufactured SolarEdge Technology

Business Wire

time6 minutes ago

  • Business Wire

SolarEdge and Solar Landscape Sign Strategic Agreement for American-Manufactured SolarEdge Technology

MILPITAS, Calif.--(BUSINESS WIRE)--SolarEdge Technologies, Inc. (NASDAQ: SEDG), a global leader in smart energy technology, and Solar Landscape, the leading U.S. commercial rooftop solar developer, today announced an agreement for the supply of SolarEdge's U.S.-manufactured solar technology for over 500 commercial rooftop projects across multiple states, to be built in 2025 and 2026. SolarEdge's domestically manufactured solar technology enables developers like Solar Landscape to meet demand for U.S.-manufactured solutions while optimizing project timelines through a localized supply chain. SolarEdge's domestically manufactured solar technology enables developers like Solar Landscape to meet demand for U.S.-manufactured solutions, while optimizing project timelines through a localized supply chain. Share The collaboration will focus on accelerating solar deployment across large-scale commercial and industrial rooftops, which remain a largely untapped resource for distributed generation (DG) solar. SolarEdge's advanced technology enables efficient installations on a wide range of commercial rooftops, generating more power from the available space. "Generating electricity on commercial rooftops and distributing it into the grid is America's most shovel-ready energy option," said Solar Landscape's co-founder and CEO Shaun Keegan. "Our partnership with SolarEdge allows us to rapidly and efficiently deploy solar across a diverse array of commercial and industrial rooftops. Their U.S.-manufactured technology gives us the reliability and performance we need while meeting domestic content requirements for our projects." "We are proud to partner with Solar Landscape to accelerate the adoption of commercial solar across America," said Naama Ohana, Chief Commercial & Industrial Division at SolarEdge. "Our domestic manufacturing facilities have already created approximately 2,000 American jobs while ensuring a resilient supply chain for our partners. This collaboration demonstrates how American innovation and manufacturing is helping to address the nation's growing energy needs while strengthening local economies." In 2024 Solar Landscape leased 40 million square feet of commercial rooftop space in the U.S. The company aims to deploy enough solar capacity to power 80,000 households. Solar Landscape now has over 80 partners that own over 2 billion square feet of commercial real estate nationwide. About SolarEdge SolarEdge is a global leader in smart energy technology. By leveraging world-class engineering capabilities and with a relentless focus on innovation, SolarEdge creates smart energy solutions that power our lives and drive future progress. SolarEdge developed an intelligent inverter solution that changed the way power is harvested and managed in photovoltaic (PV) systems. The SolarEdge DC optimized inverter seeks to maximize power generation while lowering the cost of energy produced by the PV system. Continuing to advance smart energy, SolarEdge addresses a broad range of energy market segments through its PV, storage, EV charging, batteries, and grid services solutions. SolarEdge is online at About Solar Landscape Solar Landscape is the nation's leading commercial rooftop solar developer. With 800 megawatts of solar across 75 million square feet of rooftop space, the company brings unmatched scale and expertise to the commercial real estate industry. Solar Landscape partners with the country's largest property owners to transform underutilized rooftops into reliable, revenue-generating solar assets. Founded by construction professionals, Solar Landscape is a vertically integrated company that develops, builds, owns, and operates solar projects nationwide. The company was named the #1 National Commercial Rooftop Solar Developer by Solar Power World in 2025, recognized as the #1 Distributed Generation Developer by New Project Media, and awarded the U.S. Department of Energy's Grand Prize for clean energy. Visit for more information.

Generative Pulse is Here: At Last Brands Can Take Control of AI Narratives
Generative Pulse is Here: At Last Brands Can Take Control of AI Narratives

Hamilton Spectator

time21 minutes ago

  • Hamilton Spectator

Generative Pulse is Here: At Last Brands Can Take Control of AI Narratives

Miami, July 30, 2025 (GLOBE NEWSWIRE) — Generative Pulse , a groundbreaking new solution for shaping brand visibility in generative AI responses, is now available, providing brands with the insights and tools they need to understand and guide how they appear in AI answers. Developed by Muck Rack, the leader in PR software, Generative Pulse empowers communicators to identify the sources shaping AI responses, engage key voices, steer the narrative, and measure impact, all in one platform. As tools like ChatGPT, Claude and Gemini increasingly become the first stop for information-seekers, how these AI models describe brands is transforming customer perception, purchase behavior and even reputation. Generative Pulse is the first PR-specific tool built to address this shift, revealing which journalists, outlets, and sources are driving how AI talks about a brand, and enabling communications teams to influence the conversation directly. 'Brands that aren't showing up in AI-generated answers aren't showing up at all,' said Greg Galant, cofounder and CEO of Muck Rack. 'This is a turning point for PR. With Generative Pulse, we're giving comms teams the insight and actionability they need to lead in the era of generative search.' New Research: AI Trusts Earned Media The launch follows the release of Muck Rack's new, benchmark-setting research report, What Is AI Reading? , which analyzed over 1 million links cited by AI platforms. The findings show that over 95% of links cited by AI are from non-paid media, and 89% are earned media. Journalistic content makes up 27% of all citations, rising to 49% for recent or time-sensitive queries. High-authority outlets like Reuters , Axios , Financial Times and AP dominate citations, but industry-specific sources are frequently pulled depending on the query type and topic. From Insight to Action: Inside Generative Pulse Generative Pulse delivers a unique dashboard experience built around Generative Engine Optimization (GEO)—a new framework for AI-era brand visibility. Muck Rack users can input brand names, competitors and prompts, and get a full report including: 'No other platform connects insight to action like Generative Pulse,' added Galant. 'You're not just seeing who's influencing AI, you can actually reach them, influence the outcome and measure your impact all within the same workflow.' Platform Integration and Availability GEO functionality must be integrated into a complete PR workflow and earned media suite so teams can actively shape how LLMs respond; not just passively monitor the results. Muck Rack integrates these insights into its end-to-end PR workflow, enabling users to instantly pitch the most influential journalists, add top-cited outlets to media lists and analyze the news and social media for stories that will impact how they show up in LLM answers. Generative Pulse is available now as part of Muck Rack Premier. It uses the same interface trusted by more than 5,000 companies globally and builds on Muck Rack's fully integrated platform for media relations, including its global media monitoring tools, industry-leading media database, and integrated pitching, press release and social listening tools. Ready to see Generative Pulse in action? Request a demo . # # # About Generative Pulse Generative Pulse is a tool that helps PR and communications teams monitor and define how their brands appear in AI-generated search results. Built around the concept of Generative Engine Optimization (GEO), which is also referred to as Artificial Intelligence Optimization (AIO), Answer Engine Optimization (AEO), or Artificial Intelligence for Search Engine Optimization (AI SEO), it reveals which journalists, outlets, and sources influence large language models like ChatGPT—so teams can shape brand visibility in the age of AI. Integrated into Muck Rack's PR platform and backed by a $180M Series A financing, Generative Pulse gives comms professionals the insights and tools to lead in an AI-native search landscape. Learn more at About Muck Rack Muck Rack is the leading provider of award-winning PR software built for how brands and agencies work. The only public relations software powered by intuitive technology and the most accurate, comprehensive data provided by journalists themselves, Muck Rack combines media database, monitoring and reporting for seamless team collaboration, pitching and measurement. Purpose-built for communications and public relations, Muck Rack helps more than 5,000 companies worldwide analyze and report on the impact of their media relations. Thousands of journalists use Muck Rack's free tools to showcase their portfolios, analyze news about any topic and measure the impact of their stories. Learn more at . We're Hiring !

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store